iBio Presents New Preclinical Data Across Obesity and Cardiometabolic Portfolio At PEGS Europe 2026 And Amylin-Based Therapeutics Summit
Benzinga Newsdesk 1 day ago
BiotechGeneralNewsEvents
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
ObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28.Amylin program data demonstrating
ObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28.
Amylin program data demonstrating reduced food intake in rats to be presented at PEGS Europe and the Amylin-Based Therapeutics Summit
Together, the findings highlight the potential of iBio’s antibody discovery platform to generate highly specific candidates against distinct targets
